vival are higher in patients with early perfusion of the infarct-related artery than in those in whom reperfusion fails.8 Most recently, a pteliminary analysis from the Thrombolysis in Myocardial Infarction (TIMI) trial found better 6 month survival after successful thrombolysis with both t-PA and streptokinase.9 The Western Washington Trial found that the perfusion status of the vessel was an independent predictor of in-hospital and 1 year survival, even after consideration of left ventricular function.10
Percutaneous transluminal coronary angioplasty (PTCA) has been advocated as a method of salvaging vessel patency in patients in whom pharmacologic thrombolysis fails. 6 11 This strategy has been shown to be feasible in patients in whom therapy with streptokinase failed,6' 11 or as a primary procedure,'2 but the results of the strategy of rescue PTCA have not been examined in patients in whom t-PA fails. The purposes of this investigation were to examine the clinical factors associated with failure of t-PA and to determine the clinical course of these patients when treated with an aggressive strategy of rescue PTCA.
Methods
Patient population. Patients were considered for entry into this protocol if they had symptoms of acute myocardial infarction for less than 4 hr or if they had persistent severe symptoms between 4 and 6 hr after onset.2 Patients who had had symptoms for less than 20 min or who had prompt relief of symptoms with sublingual nitroglycerin were excluded. Additionally, patients over age 75 and those with a recent history of cerebrovascular disease, surgery, trauma or bleeding, or a history of coronary artery bypass grafting were excluded. Electrocardiographic criteria for inclusion were the presence of ST segment elevation of 1 or more mm in at least two contiguous leads in the absence of a previous Q wave infarction in the same infarct-related artery distribution. Patients with cardiogenic shock at the initial physical examination also were excluded. motion was analyzed by use of the centerline chord method. '5 Data collection and analysis. Multiple data items were collected prospectively by the study nurses throughout the patients' clinical courses. These findings were forwarded to the Biostatistical Coordinating Center for data entry and review for quality. All major end points were checked against the clinical record. After completion of the trial the ventriculographic data were added to the dataset. Follow-up at least 6 months after the initiation of therapy was obtained by telephone call or clinic visit for all patients. Frequencies in different subgroups were tabulated with use of medians and percentile ranges. Because of the exploratory, observational nature of the data and the possibility of multiple comparisons, statistical tests were not used to compare subgroups.
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Results
Baseline characteristics. The clinical characteristics of patients in the t-PA failure group compared with those of patients with perfusion of the infarct-related vessel are shown in table 1. No differences were observed with regard to demographics, clinical history, or major cardiac risk factors, except that 20 of 22 black patients had successful reperfusion. Nadir fibrinogen values were marginally lower and peak fibrin degradation product 1092 ison, the population was divided into four groups with regard to initial treatment strategy (table 6). Patients in whom t-PA failed who underwent an attempted immediate PTCA had a 12% in-hospital mortality and a 29% reocclusion rate. No deaths occurred among the 10 patients who did not undergo an attempted PTCA. This group of patients had a high rate of subsequent CABG, mostly because of clinical judgment that the infarct zone was small so that emergency PTCA was not indicated, but that coexisting prognostically significant disease mandated CABG before hospital discharge. No other striking differences in clinical outcomes were apparent among the groups.
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Of the 10 patients who died after attempted PTCA in the t-PA failure group, all had proximal coronary lesions. Five of these patients developed cardiogenic shock after enrollment in the trial, but before attempted PTCA. One additional patient had severe refractory arrhythmias before attempted PTCA. Of the remaining four patients, one developed a ventricular septal defect on day 7, one patient with proximal left anterior descending occlusion and concomitant proximal right and circumflex disease developed cardiogenic shock during attempted PTCA and died in power failure despite emergency CABG, one patient died from apparent reocclusion, and one patient died from refractory right ventricular infarction. Values are percents of patients.
AGne patient had delayed reperfusion after 90 min followed by reocclusion.
BUrgent CABG is defined as operative procedure beyond 6 hours but before 7 days from initiation of t-PA therapy. onset and reperfusion has been reported with t-PA,21 but this differs dramatically from results with streptokinase.13' 21. 22 The association of failure to reperfuse with right coronary obstruction has been reported by others, but the difference was so small as to be of little clinical relevance. 22 Further delineation of the pathophysiology of failure to reperfuse will depend on improved understanding of the structure of the atherosclerotic plaque, the direct environment around the thrombus, and possibly the presence of a fibrinolytic defect or resistance to fibrinolysis. In some patients, hemorrhage into the plaque23, 24 may be a major factor, leading to greater obstruction of the vessel with thrombolysis due to continued expansion of the plaque. In other patients the length of the underlying plaque and thrombus, or the flow characteristics in the particular area involved, may prevent adequate penetration of the thrombus by t-PA. A systemic inhibitor of t-PA has been isolated and found to be present in increased amounts in young patients after acute myocardial infarction. 25 Although an insufficient quantity of the inhibitor is likely to be present to offset pharmacologic doses of t-PA (therapeutic levels of t-PA exceed endogenous levels by a factor greater than 1000), assays in studies of the acute phase of myocardial infarction have not been made to date. Our measurements of fibrinogen levels also demonstrate the absence of a relationship between systemic fibrinogenolysis and successful t-PA-mediated reperfusion; the opposite finding has been reported with streptokinase. 26 The clinical course before interventional cardiac catheterization did not allow patients in the t-PA success group to be distinguished from those in the t-PA failure group with use of clinical variables. Major complications were rare in both groups, although transient hypotension and severe sinus bradycardia were common. Both of these complications were readily amenable to therapeutic intervention.
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Course during interventional catheterization. The clinical courses of patients with and without pharmacologic perfusion diverged on entry into the cardiac catheterization laboratory. Although a high rate of angiographic success with PTCA was achieved in the patients in the t-PA failure group, serious complications were much more frequent in this group. Whether these complications reflected continued evolution of the infarct in these patients, or a direct effect of the interventional procedure, cannot be determined from this study. A previous study by Timmis et al. 27 suggested that PTCA-induced reperfusion led to a higher rate and severity of "reperfusion arrhythmias" compared with intracoronary streptokinase, perhaps because of the rapidity of reperfusion. However, many of the complications in our study did not result from attempted PTCA, since ventricular fibrillation occurred in two of 10 patients who did not undergo PTCA, while complete heart block, transient hypotension, sustained hypotension, and respiratory arrest occurred in one patient each without attempted PTCA. Furthermore, cardiogenic shock had developed in a subset of patients between initiation of therapy and attempted PTCA. A higher rate of complications during interventional catheterization after failure of streptokinase was also reported by Stack et al.,6 while Fung et al.1`reported few complications in a similar population. No other comparative reports are available. Until further information is generated, clinicians attempting mechanical recanalization therapy of patients in whom t-PA therapy has failed should be prepared to treat frequent ventricular arrhythmias and hypotension. Early intra-aortic balloon counterpulsation should be considered in patients with hemodynamic distress.
In-hospital outcomes. Several previous studies have related early patency of the infarct-related artery after streptokinase therapy to subequent mortality. The low mortality in patients with successful PTCA and high mortality in patients with PTCA failure in this group could be interpreted several ways. Combined with the previously presented information about the prognostic importance of pharmacologic recanalization, one interpretation is that vigorous efforts to achieve mechanical recanalization are justified because success will lead to a low mortality. Alternatively, angioplasty could simply serve as a means to distinguish the patient with a good from the patient with a poor prognosis based on the same characteristics that make them amenable to PTCA. Another possible conclusion is that PTCA actually was detrimental to patients in whom it failed, because of the high mortality in this group. We do not think that this latter interpretation is tenable because of the high-risk characteristics of patients who failed PTCA; many were in shock before cardiac catheterization.
Reocclusion In conclusion, patients in whom reperfusion with intravenous t-PA fails have a poorer prognosis than those in whom it is successful, and this poorer prognosis extends from the technical PTCA success rate to reocclusion and in-hospital mortality. Despite the problems encountered with immediate salvage PTCA, the majority of patients so treated were discharged from the hospital with a patent vessel. The excellent long-term survival in these patients after definitive recanalization of the infarct-related vessel suggests that they may benefit despite lack of left ventricular functional improvement. The cause of thrombolytic failure in these patients has not been elucidated. New methods to achieve successful reperfusion and sustained patency in patients who fail to recanalize with lytic therapy are warranted. Synergy of lytic agents, new mutants or hybrids, and mechanical devices such as the intimal stent may change the outlook for these patients in the future.
